Rosetta Genomics Ltd. develops and commercializes a range of microRNA-based diagnostic tools. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including miRview mets2, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; miRview meso to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; miRview lung, a lung cancer classification test for cytology samples; and miRview kidney, a microRNA-based kidney tumor classification test for pathology samples. It also distributes miRview mets for identification of the origin of the primary tumor of metastases; and miRview squamous for differentiating squamous from non squamous non-small cell lung cancer. The company also focuses on developing blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool

• [07/24/2014 23:05 PDT] ROSG Are Seasonally Ripe To Go Down In the Next Five Weeks
• [06/26/2014 22:29 PDT] ROSG Are Seasonally Ripe To Go Down In the Next Five Weeks
• [05/26/2014 01:10 PDT] ROSG Are Seasonally Ripe To Go Down In the Next Five Weeks